Albina N Minlikeeva1, Jo L Freudenheim2, Rikki A Cannioto1, J Brian Szender3, Kevin H Eng4, Francesmary Modugno5,6,7, Roberta B Ness8, Michael J LaMonte2, Grace Friel1, Brahm H Segal9,10, Kunle Odunsi3,11, Paul Mayor3, Emese Zsiros11, Barbara Schmalfeldt12, Rüdiger Klapdor13, Thilo Dӧrk13, Peter Hillemanns13, Linda E Kelemen14, Martin Kӧbel15, Helen Steed16, Anna de Fazio17, Susan J Jordan18, Christina M Nagle18,19, Harvey A Risch20, Mary Anne Rossing21, Jennifer A Doherty22, Marc T Goodman23, Robert Edwards6,7, Keitaro Matsuo24, Mika Mizuno25, Beth Y Karlan26, Susanne K Kjær27,28, Estrid Høgdall27,29, Allan Jensen27, Joellen M Schildkraut30, Kathryn L Terry31, Daniel W Cramer31, Elisa V Bandera32, Lisa E Paddock33,34, Lambertus A Kiemeney35, Leon F Massuger35, Jolanta Kupryjanczyk36, Andrew Berchuck37, Jenny Chang-Claude38,39, Brenda Diergaarde40, Penelope M Webb18, Kirsten B Moysich41,42,43. 1. Deparment of Cancer Prevention and Control, Roswell Park Cancer Institute, A-352 Carlton House, Elm and Carlton Streets, Buffalo, NY, 14263, USA. 2. Deparment of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY, USA. 3. Department of Surgery, Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA. 4. Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA. 5. Department of Epidemiology, University of Pittsburgh, and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. 6. Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. 7. Department of Obstetrics, Gynecology and Reproductive Sciences and Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. 8. The University of Texas, School of Public Health, Houston, TX, USA. 9. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA. 10. Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA. 11. Center of Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA. 12. Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 13. Department of Obstetrics and Gynecology, Hannover Medical School, Hanover, Lower Saxony, Germany. 14. Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA. 15. Department of Pathology and Laboratory Medicine, Foothills Medical Center, University of Calgary, Calgary, AB, Canada. 16. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Royal Alexandra Hospital, Edmonton, AB, Canada. 17. Department of Gynecological Oncology, Westmead Hospital and the Westmead Millenium Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia. 18. Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. 19. School of Public Health, The University of Queensland, Brisbane, QLD, Australia. 20. Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA. 21. Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 22. Department of Epidemiology, The Geisel School of Medicine at Dartmouth Medical, Hanover, NH, USA. 23. Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 24. Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan. 25. Department of Gynecological Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan. 26. Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 27. Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark. 28. Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 29. Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark. 30. Department of Public Health Sciences, School of Medicine, University of Virginia, Charlottesville, VA, USA. 31. Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA. 32. Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. 33. New Jersey Department of Health and Senior Services, Trenton, NJ, USA. 34. School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA. 35. Radboud University Medical Center, Radboud Institute for Health Sciences, and Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. 36. Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. 37. Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA. 38. Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany. 39. University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 40. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. 41. Deparment of Cancer Prevention and Control, Roswell Park Cancer Institute, A-352 Carlton House, Elm and Carlton Streets, Buffalo, NY, 14263, USA. kirsten.moysich@roswellpark.org. 42. Deparment of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY, USA. kirsten.moysich@roswellpark.org. 43. Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA. kirsten.moysich@roswellpark.org.
Abstract
PURPOSE: Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype. METHODS: Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes. RESULTS: History of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94. CONCLUSIONS: Histories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.
PURPOSE: Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancerpatients has not been studied extensively, particularly according to histological subtype. METHODS: Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes. RESULTS: History of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94. CONCLUSIONS: Histories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancerpatients. Understanding mechanisms for these observations could provide insight regarding treatment.
Entities:
Keywords:
Beta blockers; Diabetes; Hypertension; Medications; Mortality; Ovarian cancer prognosis
Authors: Marc T Goodman; Galina Lurie; Pamela J Thompson; Katharine E McDuffie; Michael E Carney Journal: Endocr Relat Cancer Date: 2008-07-30 Impact factor: 5.678
Authors: Susan K Lutgendorf; Steven Cole; Erin Costanzo; Sarah Bradley; Jeremy Coffin; Sarvenaz Jabbari; Kaitlin Rainwater; Justine M Ritchie; Maria Yang; Anil K Sood Journal: Clin Cancer Res Date: 2003-10-01 Impact factor: 12.531
Authors: Tianyi Huang; Elizabeth M Poole; A Heather Eliassen; Olivia I Okereke; Laura D Kubzansky; Anil K Sood; John P Forman; Shelley S Tworoger Journal: Int J Cancer Date: 2016-03-25 Impact factor: 7.396
Authors: Weiva Sieh; Shannon Salvador; Valerie McGuire; Rachel Palmieri Weber; Kathryn L Terry; Mary Anne Rossing; Harvey Risch; Anna H Wu; Penelope M Webb; Kirsten Moysich; Jennifer A Doherty; Anna Felberg; Dianne Miller; Susan J Jordan; Marc T Goodman; Galina Lurie; Jenny Chang-Claude; Anja Rudolph; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Elisa V Bandera; Sara H Olson; Melony G King; Lorna Rodriguez-Rodriguez; Lambertus A Kiemeney; Tamara Marees; Leon F Massuger; Anne M van Altena; Roberta B Ness; Daniel W Cramer; Malcolm C Pike; Celeste Leigh Pearce; Andrew Berchuck; Joellen M Schildkraut; Alice S Whittemore Journal: Int J Epidemiol Date: 2013-04 Impact factor: 7.196
Authors: Jill S Barnholtz-Sloan; Ann G Schwartz; Faisal Qureshi; Suzanne Jacques; John Malone; Adnan R Munkarah Journal: Am J Obstet Gynecol Date: 2003-10 Impact factor: 8.661
Authors: Marie Soegaard; Allan Jensen; Estrid Høgdall; Lise Christensen; Claus Høgdall; Jan Blaakaer; Susanne K Kjaer Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-06 Impact factor: 4.254
Authors: Joellen M Schildkraut; Lauren C Peres; Traci N Bethea; Fabian Camacho; Deanna Chyn; Emily K Cloyd; Elisa V Bandera; Alicia Beeghly-Fadiel; Loren Lipworth; Charlotte E Joslin; Faith G Davis; Patricia G Moorman; Evan Myers; Heather M Ochs-Balcom; Veronica Wendy Setiawan; Malcolm C Pike; Anna H Wu; Lynn Rosenberg Journal: Cancer Causes Control Date: 2019-06-24 Impact factor: 2.506
Authors: Albina N Minlikeeva; Jo L Freudenheim; Kevin H Eng; Rikki A Cannioto; Grace Friel; J Brian Szender; Brahm Segal; Kunle Odunsi; Paul Mayor; Brenda Diergaarde; Emese Zsiros; Linda E Kelemen; Martin Köbel; Helen Steed; Anna deFazio; Susan J Jordan; Peter A Fasching; Matthias W Beckmann; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Jenny Chang-Claude; Marc T Goodman; Thilo Dörk; Robert Edwards; Francesmary Modugno; Roberta B Ness; Keitaro Matsuo; Mika Mizuno; Beth Y Karlan; Ellen L Goode; Susanne K Kjær; Estrid Høgdall; Joellen M Schildkraut; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Lisa E Paddock; Lambertus A Kiemeney; Leon F A G Massuger; Rebecca Sutphen; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Celeste L Pearce; Anna H Wu; Jolanta Kupryjanczyk; Allan Jensen; Penelope M Webb; Kirsten B Moysich Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-09 Impact factor: 4.090
Authors: Albina N Minlikeeva; Jo L Freudenheim; Rikki A Cannioto; Kevin H Eng; J Brian Szender; Paul Mayor; John L Etter; Daniel W Cramer; Brenda Diergaarde; Jennifer A Doherty; Thilo Dörk; Robert Edwards; Anna deFazio; Grace Friel; Marc T Goodman; Peter Hillemanns; Estrid Høgdall; Allan Jensen; Susan J Jordan; Beth Y Karlan; Susanne K Kjær; Rüdiger Klapdor; Keitaro Matsuo; Mika Mizuno; Christina M Nagle; Kunle Odunsi; Lisa Paddock; Mary Anne Rossing; Joellen M Schildkraut; Barbara Schmalfeldt; Brahm H Segal; Kristen Starbuck; Kathryn L Terry; Penelope M Webb; Emese Zsiros; Roberta B Ness; Francesmary Modugno; Elisa V Bandera; Jenny Chang-Claude; Kirsten B Moysich Journal: Br J Cancer Date: 2017-08-17 Impact factor: 9.075